|
|
Vaccine Detail
|
Personal neoantigen cancer vaccine |
| Vaccine Information |
- Vaccine Name: Personal neoantigen cancer vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Research
- Host Species for Licensed Use: None
- Antigen: neoantigens (Fritsch et al., 2014)
- Immunization Route: Other
- Description: Neoantigen-based cancer vaccines are designed to target the unique immunogenic mutations arising in each patient's tumor. Peptide binding to MHC is a critical gateway to both the initiation of a T-cell immune response by the antigen presenting cell (APC), and to the detection and elimination of tumor cells presenting the particular peptide by the stimulated cytotoxic T lymphocyte (CTL). The attraction of neoantigens as cancer targets for the immune system results from the structural and geographical features of the mutation. Neoantigen peptides are only found in tumor cells, so CTLs should show exquisite specificity, reducing the opportunity for autoimmune disease. (Fritsch et al., 2014)
|
| Host Response |
|
|
| References |
Fritsch et al., 2014: Fritsch EF, Hacohen N, Wu CJ. Personal neoantigen cancer vaccines: The momentum builds. Oncoimmunology. 2014; 3; e29311. [PubMed: 25101225].
|
|
